In 1–5% of glioblastomas, the 1p36 locus was reported to be homozygously deleted which frequently includes ENO1. As a consequence, patients with such tumours should be more responsive to glycolysis inhibition despite the fact that ENO2 compensates for ENO1 deficiency to some extent. Here, ENO2 is linked to neoplasm.